Blair William & Co. IL Raises Position in argenex SE (NASDAQ:ARGX)

Key Points

• Blair William & Co. IL increased its position in argenex SE by 127.5%, owning 2,079 shares worth $1,230,000 as of its recent SEC filing.
• Hedge funds and institutional investors now hold 60.32% of argenex's stock, reflecting a growing interest among investment firms in the company.
• argenex reported earnings of $3.74 per share, significantly exceeding analyst expectations of $2.84, indicating strong financial performance.

Blair William & Co. IL raised its holdings in argenex SE (NASDAQ:ARGX - Free Report) by 127.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,079 shares of the company's stock after buying an additional 1,165 shares during the period. Blair William & Co. IL's holdings in argenex were worth $1,230,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GeoWealth Management LLC boosted its position in argenex by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares during the period. FIL Ltd purchased a new position in argenex in the 4th quarter valued at approximately $38,000. Rakuten Securities Inc. boosted its position in argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after buying an additional 22 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in argenex in the 4th quarter valued at approximately $38,000. Finally, Golden State Wealth Management LLC purchased a new position in argenex in the 1st quarter valued at approximately $44,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenex Stock Performance

NASDAQ ARGX opened at $661.83 on Friday. The firm has a market cap of $40.50 billion, a PE ratio of 33.94, a P/E/G ratio of 0.76 and a beta of 0.39. argenex SE has a one year low of $510.05 and a one year high of $696.21. The firm's fifty day moving average is $580.54 and its two-hundred day moving average is $597.74.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The business had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. Research analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on ARGX. Robert W. Baird raised shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research report on Tuesday, May 13th. JMP Securities set a $699.00 price objective on shares of argenex in a research report on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $715.00 price objective on shares of argenex in a research report on Monday, July 21st. Guggenheim lifted their price objective on shares of argenex from $1,060.00 to $1,070.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of argenex from $775.00 to $830.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. Eighteen analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $746.81.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.